KR940006584A - 멀미 및 구토 치료용 6-헤데로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌 - Google Patents

멀미 및 구토 치료용 6-헤데로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌 Download PDF

Info

Publication number
KR940006584A
KR940006584A KR1019930020227A KR930020227A KR940006584A KR 940006584 A KR940006584 A KR 940006584A KR 1019930020227 A KR1019930020227 A KR 1019930020227A KR 930020227 A KR930020227 A KR 930020227A KR 940006584 A KR940006584 A KR 940006584A
Authority
KR
South Korea
Prior art keywords
tetrahydrobenz
indole
propylamino
alkyl
hydrogen
Prior art date
Application number
KR1019930020227A
Other languages
English (en)
Inventor
놀란 부허 리챠드
에드워드 플로이 마이클
어니스트 로우혼 데이비드
존슨 파게트 쥬니어 찰스
메너트 쇼우즈 존
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR940006584A publication Critical patent/KR940006584A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

본 발명은 특정 6-헤테로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌 및 그에 적합한 약학제를 이용한 구토 및 멀미 치료방법을 제공한다. 본 발명의 방법에 유용한 특정화합물은 신규하며 따라서 이와 같은 화합물, 그의 제조방법, 그의 이용방법 및 그의 약학 제제도 제공한다.

Description

멀미 및 구토 치료용 6-헤테로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 구토 또는 멀미 치료용 약제를 제조하기 위한, 하기 일반식의 화합물 또는 그의 약학적으로 허용가능한 염의용도 :
    상기식에서, R1은 수소, C1-C4알킬, C3-C4알케닐, 시클로프로필 메틸, 아릴(C1-C4알킬), -(CH2)nS(C1-C4알킬), -C(O)R4또는 -(CH2)nC(O)NR5R6이고, R2는 수소, C1-C4알킬, 시클로프로필메틸 또는 C3-C4알케닐이고, R3은 수소, C1-C4알킬 또는 아미노-차단 그룹이고, n은 1 내지 4이고, R4는 수소, C1-C4알킬, C1-C4할로알킬, C1-C4알콕시 또는 페닐이고, R5및 R6은 독립적으로 수소, C1-C4알킬, 또는 C5-C8시클로알킬이고, 단 R5와 R6중 하나가 시클로알킬일 경우, 다른 하나는 수소이고, HET는 황, 산소 및 질소로 구성되는 군으로부터 선택되는 같거나 다른 1 내지 3의 헤테로원자를 가지는, 테트라졸릴 고리, 치환된 테트라졸릴 고리 또는 방향족 5-또는 6-원 헤테로시클릭 고리이고, 단 6-원 헤테로시클릭 고리는 탄소 및 질소만을 함유할 수 있고, 5-원 고리는 오직 하나의 산소 또는 하나의 황만을 함유하며 산소와 황 둘다를 함유하지 않는다.
  2. 제1항에있어서, 화합물이 (+)(4S)-6-(3-이속사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌, (-)(4R)-6-(5-이속사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌, (±)-6-(3-피라졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈-[cd]인돌; (-)(4R)-6-(4-피라졸릴)-4-(디메틸아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌, (-)(4R)-6-(4-피리딜)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌, (±)-6-(2-피리딜)-4(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈-[cd]인돌; (-)(4R)-6-(2-티아졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(5-티아졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(5-이속사졸릴)-4-[디-(시클로프로필메틸)아미노]-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(3-이속사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(3-피라졸릴)-4[디-(기클로프로필메틸)아미노]-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(3-피라졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌;(-)(4R)-6-(3-페닐옥사디아졸-5-일)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(2-옥사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(-옥사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌; (-)(4R)-6-(5-옥사졸릴)-4-[디-(시클로프로필메틸)아미노]-1,3,4,5-테트라하이드로벤즈[cd]인돌 및 그의 약학적으로 허용가능한 염으로 구성되는 군으로부터 선택된 용도.
  3. 제2항에 있어서, 화합물이 (-)(4R)-6-(2-옥사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌 또는 그의 약학적으로 허용가능한 염인 용도.
  4. 제2항에 있어서, 화합물이 (-)(4R)-6-(5-옥사졸릴)-4-(디-n-프로필아미노)-1,3,4,5-테트라하이드로벤즈[cd]인돌 또는 그의 약학적으로 허용가능한 염인 용도.
  5. 하나 또는 그 이상의 약학적으로 허용가능한 담체, 희석제 또는 부형제와 함께, 제1항 내지 제4항 중의 어느 한 항에 제시된 화합물 또는 그의 약학적으로 허용가능한 염을 포함하는, 구토 또는 멀미 치료용 약학제제.
  6. 하기 일반식의 화합물 또는 그의 약학적으로 허용가능한 염.
    상기식에서, R1은 수소, C1-C4알킬, C3-C4알케닐, 시클로프로필 메틸, 아릴(C1-C4알킬), -(CH2)nS(C1-C4알킬), -C(O)R4또는 -(CH2)nC(O)NR5R6이고, R2는 수소, C1-C4알킬, 시클로프로필메틸 또는 C3-C4알케닐이고, R3은 수소, C1-C4알킬 또는 아미노-차단 그룹이고, n은 1 내지 4이고, R4는 수소, C1-C4알킬, C1-C4할로알킬, C1-C4알콕시 또는 페닐이고, R5및 R6은 독립적으로 수소, C1-C4알킬, 또는 C5-C8시클로알킬이고, 단 R5와 R6하나가 시클로알킬일 경우, 다른 하나는 수소이고, HET는 테트라졸릴 고리 또는 치환된 테트라졸릴 고리이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930020227A 1992-09-30 1993-09-28 멀미 및 구토 치료용 6-헤데로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌 KR940006584A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/954,105 US5364856A (en) 1991-03-28 1992-09-30 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US954,105 1992-09-30

Publications (1)

Publication Number Publication Date
KR940006584A true KR940006584A (ko) 1994-04-25

Family

ID=25494930

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930020227A KR940006584A (ko) 1992-09-30 1993-09-28 멀미 및 구토 치료용 6-헤데로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌

Country Status (15)

Country Link
US (10) US5364856A (ko)
EP (2) EP1000621A3 (ko)
JP (1) JPH06211655A (ko)
KR (1) KR940006584A (ko)
CN (1) CN1056144C (ko)
AU (1) AU676849B2 (ko)
CA (1) CA2107010A1 (ko)
CZ (1) CZ9302010A3 (ko)
HU (1) HUT66076A (ko)
IL (1) IL107125A (ko)
MX (1) MX9305998A (ko)
NO (1) NO933477L (ko)
RU (1) RU2138262C1 (ko)
TW (1) TW248558B (ko)
ZA (1) ZA937153B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5347013A (en) * 1991-03-28 1994-09-13 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles
US5656653A (en) * 1991-03-28 1997-08-12 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[cd]indoles
TW248556B (ko) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US5385928A (en) * 1994-05-18 1995-01-31 Eli Lilly And Company Tetrahydrobenz [CD] indazoles, compositions and use
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1083918A1 (en) * 1998-06-08 2001-03-21 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
AU4641400A (en) * 1999-06-02 2000-12-18 Ishihara Sangyo Kaisha Ltd. Fused tricyclic compounds, process for their preparation, and herbicidal compositions containing them
US6770596B1 (en) 2000-04-21 2004-08-03 Ishihara Sangyo Kaisha Ltd. Fused tricyclic compounds, process for their preparation, and herbicidal compositions containing them
WO2013148458A1 (en) 2012-03-30 2013-10-03 Clarient Diagnostic Services, Inc. Methods for generating an image of a biological sample
CN111265268A (zh) * 2018-12-05 2020-06-12 苏州英途康医疗科技有限公司 医疗器械

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194811A (en) * 1963-09-05 1965-07-13 Merck & Co Inc Aroyl-benzindolyl acids
BE755270A (fr) * 1969-08-27 1971-02-25 Sandoz Sa Nouveaux derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
CH517732A (de) * 1969-10-24 1972-01-15 Sandoz Ag Verfahren zur Herstellung neuer Guanidin- Verbindungen
BE757879A (fr) * 1969-10-24 1971-04-22 Sandoz Sa Derives du benzo(cd)indole, leur preparation et medicaments contenant ces derives
FI206974A (ko) * 1973-07-16 1975-01-17 Sandoz Ag
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
US4282240A (en) * 1979-11-23 1981-08-04 Merck & Co., Inc. Amino substituted tetrahydrobenzindoles
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2522658A1 (fr) * 1982-03-05 1983-09-09 Roussel Uclaf Application a titre de medicaments de derives du trans 4-amino benz (c,d) indol-5-ol ainsi que de leurs sels, compositions les renfermant, nouveaux derives et leur procede de preparation
JPS5969151A (ja) * 1982-10-13 1984-04-19 Unitika Ltd 球状イオン交換樹脂とその製造法及び吸着処理法
DE3346573A1 (de) * 1983-12-23 1985-07-04 Troponwerke GmbH & Co KG, 5000 Köln 1,3,4,5-tetrahydrobenz(c,d)indole, ein verfahren zu ihrer herstellung und ihre verwendung
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
CA1266482A1 (en) * 1984-05-24 1990-03-06 Carl Kaiser 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
DE3525564A1 (de) * 1985-07-15 1987-02-05 Schering Ag Tricyclische verbindungen mit indolstruktur, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
GB8824744D0 (en) * 1988-10-21 1988-11-30 Erba Carlo Spa Antiemesis ergoline derivatives
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US4977172A (en) * 1989-09-29 1990-12-11 Warner-Lambert Company Method of treating the symptoms of cognitive decline in an elderly patient employing (S)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)-methyl]-2-oxazolidinone
US5039820A (en) * 1990-02-26 1991-08-13 Eli Lilly And Company 4-amino-6-iodo-hexahydrobenz(cd)indoles
TW219933B (ko) * 1990-02-26 1994-02-01 Lilly Co Eli
US5212319A (en) * 1990-02-26 1993-05-18 Eli Lilly And Company Intermediates to 4-amino-hexahydrobenz[cd]indoles and processes therefor
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5397779A (en) * 1990-06-15 1995-03-14 Roussel-Uclaf Cephalosporins
US5229410A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
US5656653A (en) * 1991-03-28 1997-08-12 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[cd]indoles
US5244912A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
US5347013A (en) * 1991-03-28 1994-09-13 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists

Also Published As

Publication number Publication date
CA2107010A1 (en) 1994-03-31
RU2138262C1 (ru) 1999-09-27
NO933477L (no) 1994-04-05
EP1000621A3 (en) 2003-05-14
US5624944A (en) 1997-04-29
CZ9302010A3 (en) 1994-05-18
CN1056144C (zh) 2000-09-06
ZA937153B (en) 1995-03-27
CN1094724A (zh) 1994-11-09
MX9305998A (es) 1995-01-31
US5665743A (en) 1997-09-09
EP1000621A2 (en) 2000-05-17
US5641797A (en) 1997-06-24
AU4868293A (en) 1994-07-14
IL107125A0 (en) 1993-12-28
JPH06211655A (ja) 1994-08-02
US5665758A (en) 1997-09-09
NO933477D0 (no) 1993-09-29
US5594019A (en) 1997-01-14
US5643930A (en) 1997-07-01
US5674884A (en) 1997-10-07
HUT66076A (en) 1994-09-28
US5364856A (en) 1994-11-15
AU676849B2 (en) 1997-03-27
US5750554A (en) 1998-05-12
IL107125A (en) 1998-09-24
TW248558B (ko) 1995-06-01
HU9302749D0 (en) 1993-12-28
US5736562A (en) 1998-04-07
EP0590971A1 (en) 1994-04-06

Similar Documents

Publication Publication Date Title
KR920018043A (ko) 6-헤테로사이클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌
KR930017904A (ko) 축합 이미다조피리딘 유도체
KR940006584A (ko) 멀미 및 구토 치료용 6-헤데로시클릭-4-아미노-1,3,4,5-테트라하이드로벤즈[cd]인돌
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
RU2000115577A (ru) Новые производные пиридазина и лекарственные средства, содержащие их в качестве эффективных ингредиентов
ATE207470T1 (de) Benzoxazol- und benzothiazol-derivate als arzneimittel
RU97103132A (ru) Производные изоксазола
SI21560B (sl) 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti
KR890002155A (ko) 저혈당제로서의 푸린의 피페라지닐 유도체 및 이의 제조방법
KR927003052A (ko) 2-아릴티아졸 유도체 및 그의 약제학적 조성물
HUP0105113A2 (hu) Benzoheterociklusos vegyületek és MEK inhibitorokként történő alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények
DK586588A (da) Terapeutiske heterocycliske forbindelser
NO904134L (no) Fremgangsmaate for fremstilling av pyrazolderivater.
DE3888854D1 (de) Neue tricyclische Benzimidazole, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel.
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
RU99101864A (ru) Новое производное тиофена и содержащая его фармацевтическая композиция
ATE478048T1 (de) Pharmazeutisch aktive benzsulfonamidderivate als inhibitoren von protein-jun-kinasen
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
RU2008110961A (ru) (индол-3-ил)-гетероциклические производные в качестве агонистов каннабиноидных св1 рецепторов
ATE146780T1 (de) Verbindungen mit guanidin-struktur und diese enthaltende pharmazeutische zusammensetzungen
RU98120691A (ru) Замещенные бензиламины и содержащая их фармацевтическая композиция для лечения депрессии
KR940006817A (ko) 멀미 및 구토 치료용 6-헤테로사이클릭-4-아미노-1,2,2a,3,4,5-헥사하이드로벤즈[cd]인돌
KR890009867A (ko) 비 펩타이드성 레닌 억제제
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application